Strategies in developing promising histone deacetylase inhibitors

Medicinal Research Reviews

Volumn 30, Issue 4, 2010, Pages 585-602

  Zhang, Lei ^a   Fang, Hao ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Computational techniques; Histone deacetylase inhibitors; Natural products; Probes; Selectivity

Indexed keywords

APICIDIN; HC TOXIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INDOLE AMIDE DERIVATIVE; LARGAZOLE; MS 257; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PSAMMAPLIN A; ROMIDEPSIN; TRAPOXIN; TRICHOSTATIN A; TUBACIN; UNCLASSIFIED DRUG; VORINOSTAT; BIOLOGICAL PRODUCT; MOLECULAR PROBE;

BIOLOGY; CUTANEOUS T CELL LYMPHOMA; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG SELECTIVITY; DRUG TARGETING; GENOMICS; INFLAMMATION; INFORMATION SCIENCE; NEOPLASM; PROTEOMICS; REVIEW; VIRUS INFECTION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; HUMAN; METABOLISM; MOLECULAR GENETICS; MOLECULAR PROBE; PROCEDURES; SYNTHESIS;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL PRODUCTS; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR PROBES; MOLECULAR SEQUENCE DATA;

EID: 77955480670     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20169     Document Type: Review

References (107)

1. Leipe DD, Landsman D. Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily. Nucleic Acids Res 1997;25: 3693-3697. (Pubitemid 27390190)
2. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003;370:737-749. (Pubitemid 36399066)
3. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol 2004;338:17-31.
4. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51. (Pubitemid 43054973)
5. Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: From bench to clinic. J Med Chem 2008;51:1505-1529. (Pubitemid 351438836)
6. Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA 2000;97:13708-13713.
7. Sun ZW, Hampsey M. A general requirement for the Sin3-Rpd3 histone deacetylase complex in regulating silencing in Saccharomyces cerevisiae. Genetics 1999;152:921-932. (Pubitemid 29330893)
8. Foglietti C, Filocamo G, de Rinaldis E, Lahm A, Cortese R, Steinkuhler C. Dissecting the biological functions of drosophila histone deacetylases by RNA interference and transcriptional profiling. J Biol Chem 2006;281:17968-17976. (Pubitemid 44035596)
9. Lagger G, O'Carrol D, Rembold M, Khier H, Tishler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeier R, Jenuwein T, Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21:2672-2681. (Pubitemid 34619383)
10. Zupkovitz G, Tishler J, Posch M, Sadzak IS, Decker T, Seiser C. Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol 2006;26: 7913-7918.
11. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, Olson EN. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21:1790-1802. (Pubitemid 47076478)
12. Vega RB, Matsuda K, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzi C, Shelton JM, Richardson JA, Karsenty G, Olson EN. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004;119:555-566. (Pubitemid 39482354)
13. Bolger TA, Yao TP. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J Neurosci 2005;25:9544-9553. (Pubitemid 41464769)
14. Zhang CL, McKinsey TA, Chang S, Antos JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002;110:479-488. (Pubitemid 35232291)
15. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004;24:8467-8476. (Pubitemid 39245069)
16. Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Herndier BG, Verdin E. HDAC7, a thymus-specific class ii histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003;18:687-698. (Pubitemid 36588585)
17. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, Matthias P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003;22:1168-1179. (Pubitemid 36313600)
18. Kovacs JJ, Murphy PJM, Gaillard S, Zaho X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601-607.
19. Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, Dorr A, Hetzer-Egger C, Henklein P, Frye R, McBurney MW, Hruby H, Jung M, Verdin E, Ott M. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 2005;3:e41.
20. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-159. (Pubitemid 33035942)
21. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002;32:606-613. (Pubitemid 35435172)
22. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y, Kaneki M. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated RasÂ-MAPK signaling in human cancer cells. Oncogene 2006;25:176-185.
23. Outeiro TF, Kontopoulos E, Altman S, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev A. Sirtuin 2 inhibitors rescue a-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007;317:516-519.
24. Garske AL, Smith BC, Denu JM. Linking SIRT2 to Parkinson's disease. ACS Chem Biol 2007;2:529-532.
25. Zheng YG, Wu J, Chen Z, Goodman M. Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy. Med Res Rev 2008;28:645-687.
26. Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 2008;14:505-528. (Pubitemid 351516876)
27. Jones P, Steinkuhler C. From natural products to small molecule ketone histone deacetylase inhibitors: Development of new class specific agents. Curr Pharm Des 2008;14:545-561. (Pubitemid 351516878)
28. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-193. (Pubitemid 29436325)
29. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46: 5097-5116.
30. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-26734. (Pubitemid 41040705)
31. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang X, Yao T. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-458.
32. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S, Yoshida M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002;21: 6820-6831.
33. Zhang X, Yuan Z, Zhang Y, Youg S, Salas-Burgos A, John K, Olashaw N, Parsons JT, Yang X, Dent SR, Yao T, Lane WS, Seto E. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 2007;27:197-213. (Pubitemid 47058299)
34. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005;102:8567-8572. (Pubitemid 40862776)
35. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, Saudou F. Histone deacetylase 6 inhibition compensates for the transport deficit in huntington's disease by increasing tubulin acetylation. J Neurosci 2007;27:3571-3583. (Pubitemid 46515140)
36. Kozikoeski AP, Chen Y, Gaysin A, Chen B, D'Annibale MA, Suto CM, Langley BC. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J Med Chem 2007;50:3054-3061. (Pubitemid 47001248)
37. Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem Biol 2003;10:383-396.
38. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective smallmolecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003;100:4389-4394.
39. Sternson SM, Wong JC, Grozinger CM, Schreiber SL. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett 2001;3:4239-4242.
40. Heltweg B, Dequiedt F, Marshall BL, Brauch C, Yoshida M, Nishino N, Verdin E, Jung M. Subtype selective substrates for histone deacetylases. J Med Chem 2004;47:5235-5243. (Pubitemid 39314921)
41. Suzuki T, Kouketsu A, Itoh Y, Hisakawa S, Maeda S, Yoshida M, Nakagawa H, Miyata N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J Med Chem 2006;49:4809-4812. (Pubitemid 44201038)
42. Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD. functional differences in epigenetic modulators - superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J Med Chem 2008;51: 4370-4373.
43. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors . Proc Natl Acad Sci USA 1999;96:4592-4597. (Pubitemid 29190381)
44. Zhou N, Moradei O, Raeppel S, Leit S, Frechette S, Gaudette F, Paquin I, Bernstein N, Bouchain G, Vaisburg A, Jin Z, Gillespie J, Wang J, Fournel M, Yan PT, Trachy-Bourget MC, Kalita A, Lu A, Rahil J, MacLeod AR, Li Z, Besterman JM, Delorme D. Discovery of N-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino) methyl] benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 2008;51:4072-4075. (Pubitemid 352032434)
45. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama N, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62:4916-4921. (Pubitemid 34984414)
46. Mai A, Massa S, Rotili D, Simeoni S, Ragno R, Botta G, Nebbioso A, Miceli M, Altucci L, Brosch G. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J Med Chem 2006;49:6046-6056. (Pubitemid 44484948)
47. Methot JL, Hamblett CL, Mampreian DM, Jung J, Harsch A, Szewczak AA, Dahlberg WK, Middleton RE, Hughes B, Fleming JC, Wang H, Kral AM, Ozerova N, Cruz JC, Haines B, Chenard M, Kenific CM, Secrist JP, Miller TA. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 2008;18:6104-6109.
48. Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM. Design and evaluation of "Linkerless" hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007;17:2874-2878.
49. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G. Class II (IIa)-selective histone deacetylase inhibitors. 1. synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides. J Med Chem 2005;48:3344-3353. (Pubitemid 40628053)
50. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001;276:38837-38843. (Pubitemid 37371246)
51. Glenn MP, Kahnberg P, Boyle GM, Hansford KA, Hans D, Martyn AC, Parsons PG, Fairlie DP. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem 2004;47:2984-2994.
52. Kahnberg P, Lucke AJ, Glenn MP, Boyle GM, Tyndall JD, Parsons PG, Fairlie DP. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from α-aminosuberic acid. J Med Chem 2006;49:7611-7622.
53. Ewing TJA, Kuntz ID. Critical evaluation of search algorithms for automated molecular docking and database screening. J Comput Chem 1997;18:1175-1189.
54. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. J Mol Biol 1982;161:269-288.
55. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-1662. (Pubitemid 128590223)
56. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996;261:470-489. (Pubitemid 26335901)
57. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748. (Pubitemid 27170693)
58. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47: 1739-1749.
59. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750-1759.
60. Hansson T, Oostenbrink C, van Gunsteren W. Molecular dynamics simulations. Curr Opin Struct Biol 2002;12:190-196.
61. Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nat Struct Biol 2002;9:646-652.
62. Norberg J, Nilsson L. Advances in biomolecular simulations: Methodology and recent applications. Q Rev Biophys 2003;36:257-306. (Pubitemid 38268659)
63. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 1995;117:5179-5197.
64. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM - A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983;4:187-217.
65. Scott WRP, Hunenberger PH, Tironi IG, Mark AE, Billeter SR, Fennen J, Torda AE, Huber T, Kruger P, van Gunsteren WF. The GROMOS biomolecular simulation program package. J Phys Chem A 1999;103:3596-3607.
66. Nelson MT, Humphrey W, Gursoy A, Dalke A, Kale LV, Skeel RD, Schulten K. NAMD: A parallel, object oriented molecular dynamics program. Int J Supercomput Appl 1996;10: 251-268.
67. Mai A, Massa S, Ragno R, Cerbara I, Jesacher F, Loidl P, Brosch G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. J Med Chem 2003;46:512-524.
68. Mai A, Massa S, Cerbara I, Valente S, Ragno R, Bottoni P, Scatena R, Loidl P, Brosch G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity. J Med Chem 2004;47:1098-1109.
69. Wang DF, Wiest O, Helquist P, Lan-Hargest HY, Wiech NL. On the function of the 14 Å long internal cavity of histone deacetylase-like protein: Implications for the design of histone deacetylase inhibitors. J Med Chem 2004;47:3409-3417.
70. Wang DF, Helquist P, Wiech NL, Wiest O. Toward selective histone deacetylase inhibitor design: Homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 2005;48:6936-6947. (Pubitemid 41533115)
71. Weerasinghe SV, Estiu G, Wiest O, Pflum MK. Residues in the 11 Å channel of histone deacetylase 1 promote catalytic activity: Implications for designing isoform-selective histone deacetylase inhibitors. J Med Chem 2008;51:5542-5551.
72. Yan CL, Xiu ZL, Li XH, Li SM, Hao C, Teng H. Comparative molecular dynamics simulations of histone deacetylase-like protein: Binding modes and free energy analysis to hydroxamic acid inhibitors. Proteins 2008;73:134-149.
73. Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110: 5959-5967.
74. Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37:4130-4146. (Pubitemid 24379702)
75. Guo YS, Xiao JF, Guo ZR, Chu FM, Cheng YH, Wu S. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses. Bioorg Med Chem 2005;13:5424-5434. (Pubitemid 41132620)
76. Katritzky AR, Slavov SH, Dobchev DA, Karelson M. Comparison Between 2D and 3D-QSAR Approaches to Correlate Inhibitor Activity for a Series of Indole Amide Hydroxamic Acids. QSAR Comb Sci 2007;26:333-345. (Pubitemid 46932860)
77. Chen YD, Li HF, Tang WQ, Zhu CC, Jiang YJ, Zou JW, Yu QS, You QD. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem 2009;44:2868-2876.
78. Chen YD, Jiang YJ, Zhou JW, Yu QS, You QD. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. J Mol Graph Model 2008;26:1160-1168.
79. Price S, Bordogna W, Bull RJ, Clark DE, Crackett PH, Dyke HJ, Gill M, Harris NV, Gorski J, Lloyd J, Lockey PM, Mullett J, Roach AG, Roussel F, White AB. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 2007;17:370-375. (Pubitemid 46073757)
80. Tang H, Wang XS, Huang XP, Roth BL, Butler KV, Kozikowski AP, Jung M, Tropsha A. Novel Inhibitors of Human Histone Deacetylase (HDAC) Identified by QSAR Modeling of Known Inhibitors, Virtual Screening, and Experimental Validation. J Chem Inf Model 2009;49:461-476.
81. Vadivelan S, Sinha BN, Rambabu G, Boppana K, Jagarlapudi SA. Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads. J Mol Graph Model 2008;26:935-946.
82. Tervo AJ, Kyrylenko S, Niskanen P, Salminen A, Leppänen J, Nyrönen TH, Järvinen T, Poso A. An in silico approach to discovering novel inhibitors of human sirtuin type 2. J Med Chem 2004;47:6292-6298. (Pubitemid 39587253)
83. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-17179. (Pubitemid 20334262)
84. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitior of mammalian histone deacetylase. J Biol Chem 1993;268:22429-22435. (Pubitemid 23318291)
85. Shute RE, Dunlap B, Rich DH. Analogues of the cytostatic and antimitogenic agents chlamydocin and HC-toxin synthesis and biological activity of chloromethyl ketone and diazomethyl ketone functionalized cyclic tetrapeptidest. J Med Chem 1987;30:71-78. (Pubitemid 17221619)
86. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, Kwon HK, Hong S, L HY, Lee YW, Lee HW. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and Gelsolin1. Cancer Res 2000;60:6068-6074.
87. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M. FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968 1. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiotics 1994;47:301-310.
88. Jung JH, Sim CJ, Lee CO. Cytotoxic compounds from a two-sponge association. J Nat Prod 1995;58:1722-1726.
89. Li CJ, Schmitz FJ, Kelly-Borges M. A new lysine derivative and new 3-bromopyrrole carboxylic acid derivative from two marine sponges. J Nat Prod 1998;61:387-389. (Pubitemid 28160733)
90. Piña IC, Gautschi JT, Wang GY, Sanders ML, Schmitz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski SW, Perez LB, Bair KW, Crews PJ. Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. Org Chem 2003;68:3866-3873. (Pubitemid 36576636)
91. Ahn MY, Jung JH, Na YJ, Kim HS. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 2008;108:27-33. (Pubitemid 350299431)
92. Taori K, Paul VJ, Luesch H. Structure and activity of largazole, a potent antiproliferative agent from the floridian marine Cyanobacterium Symploca sp. J Am Chem Soc 2008;130:1806-1807. (Pubitemid 351238618)
93. Ying Y, Taori K, Kim H, Hong J, Luesch H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc 2008;130:8455-8459. (Pubitemid 351898566)
94. Bowers A, West N, Taunton J, Schreiber SL, Bradner JE, Williams RM. Total synthesis and biological mode of action of largazole: A potent class I histone deacetylase inhibitor. J Am Chem Soc 2008;130:11219-11222.
95. Yurek-George A, Cecil AR, Mo AH, Wen S, Rogers H, Habens F, Maeda S, Yoshida M, Packham G, Ganesan A. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor. J Med Chem 2007;50:5720-5726. (Pubitemid 350106026)
96. Nishino N, Jose B, Okamura S, Ebisusaki S, Kato T, Sumida Y, Yoshida M. Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases. Org Lett 2003;5:5079-5082. (Pubitemid 38073003)
97. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996;93:5705-5708. (Pubitemid 26191313)
98. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998;95:3003-3007. (Pubitemid 28135844)
99. Marks PA, Richon VM, Rifkind RA. Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds. Int J Hematol 1996;63:1-17.
100. Webb Y, Zhou X, Ngo L, Cornish V, Stahl J, Erdjument-Bromage H, Tempst P, Rifkind RA, Marks PA, Breslow R, Richon VM. Photoaffinity labeling and mass spectrometry identify ribosomal protein S3 as a potential target for hybrid polar cytodifferentiation agents. J Biol Chem 1999;274:14280-14287. (Pubitemid 129518739)
101. Salisbury CM, Cravatt BF. Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc Natl Acad Sci USA 2007;104:1171-1176.
102. Salisbury CM, Cravatt BF. Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. J Am Chem Soc 2008;130:2184-2194.
103. Trapp J, Jochum A, Meier R, Saunders L, Marshall B, Kunick C, Verdin E, Goekjian P, Sippl W, Jung M. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem 2006;49:7307-7316. (Pubitemid 44913391)
104. Chen L, Wilson D, Jayaram HN, Pankiewicz KW. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem 2007;50:6685-6691. (Pubitemid 350309105)
105. Inai K, Tsutani H, Yamauchi T, Nakamura T, Ueda T. Differentiation and reduction of intracellular GTP levels in HL-60 and U937 cells upon treatment with IMP dehydrogenase inhibitors. Adv Exp Med Biol 1998;431:549-553. (Pubitemid 28236834)
106. Gu JJ, Santiago L, Mitchell BS. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. Blood 2005;105:3270-3277. (Pubitemid 40504349)
107. Inai K, Tsutani H, Yamauchi T, Fukushima T, Iwasaki H, Imamura S, Wano Y, Nemoto Y, Naiki H, Ueda T. Differentiation induction in non-lymphocytic leukemia cells upon treatment with mycophenolate mofetil. Leuk Res 2000;24:761-768. (Pubitemid 30649696)